It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Veins have emerged as the origin of all other endothelial cell subtypes needed to expand vascular networks during developmental and pathological neoangiogenesis. Here, we uncover the role of the angioneurin Fibronectin Leucine Rich Transmembrane protein (FLRT) 2 in central nervous system (CNS) vascular development in the mouse. Early postnatal FLRT2 deletion reveals specific defects in retinal veins, impacting endothelial cell proliferation, sprouting and polarity that result in reduced tip cells at the vascular front. FLRT2 interacts with VE-cadherin and together with the endocytic adaptor protein Numb contribute to the modulation of adherens junction morphology in both retina and cerebral cortex in vivo. Utilizing expansion microscopy, we visualize the altered dynamic distribution of VE-cadherin in tissue of FLRT2 endothelial mutants. Additionally, FLRT2 in cortical vessels regulates the crosstalk between adherens and tight junctions, influencing blood-brain barrier development. Our findings position FLRT2 as a vein-specific regulator of CNS vascular development.
Llao-Cid et al find FLRT2 (Fibronectin Leucine Rich Transmembrane protein) is present in the veins and capillaries of the central nervous system, where it regulates vascular development and the formation of the blood-brain barrier by influencing VE-cadherin turnover.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences (BMLS), Institute of Cell Biology and Neuroscience, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)
2 Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences (BMLS), Institute of Cell Biology and Neuroscience, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Max Planck Institute for Brain Research, Frankfurt am Main, Germany (GRID:grid.419505.c) (ISNI:0000 0004 0491 3878)
3 Justus Liebig University Giessen, Institute of Neuropathology, Giessen, Germany (GRID:grid.8664.c) (ISNI:0000 0001 2165 8627)
4 Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences (BMLS), Institute of Cell Biology and Neuroscience, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Cardio-Pulmonary Institute (CPI), Frankfurt am Main, Germany (GRID:grid.511808.5)
5 Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences (BMLS), Institute of Cell Biology and Neuroscience, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Max Planck Institute for Brain Research, Frankfurt am Main, Germany (GRID:grid.419505.c) (ISNI:0000 0004 0491 3878); Cardio-Pulmonary Institute (CPI), Frankfurt am Main, Germany (GRID:grid.511808.5)